Precision therapy.
Visible in real time.
Therasynthesis is developing locally manufacturable theranostic platforms that combine targeted radionuclide therapy, quantitative SPECT/CT imaging and personalised dosimetry — with the goal of making advanced cancer care simpler, better and more accessible.
Advancing locoregional radionuclide therapy through Malaysian innovation.
Therasynthesis Sdn Bhd is a Malaysian theranostic technology company focused on image-guided, targeted radionuclide therapy.
Our mission is to improve the quality and accessibility of cancer care by developing precision technologies that can be manufactured locally, delivered selectively and verified quantitatively.
Our flagship holmium-166 platform combines biodegradable microspheres and HoliRods™ with SPECT/CT imaging and personalised dosimetry. The same Ho-166 radionuclide provides therapeutic beta emission and an imaging gamma signal, supporting the principle: “Treat what we see, see what we treat.”
Our strategy brings together medical physics, biomedical engineering, interventional radiology, surgery, nuclear technology, dosimetry software and clinical translation.
Technology should heal, not divide.
We are building a locally controlled theranostic platform intended to reduce dependence on imported treatment products while supporting precision, image-guided cancer care.
HoliRods™
A biodegradable Ho-166 microsphere and rod theranostic platform for targeted tumour irradiation with built-in SPECT/CT imaging capability.
Dual-modality theranostics
Ho-166 provides therapeutic beta emission and gamma photons suitable for SPECT/CT imaging.
Biodegradable polymer carrier
PLGA-based delivery is designed to biodegrade after local delivery rather than remain as a permanent carrier.
Quantitative imaging pathway
SPECT/CT supports localisation, activity quantification and development of patient-specific dosimetry.
Local production pathway
The development model includes neutron activation at the Malaysian Nuclear Agency.
One radionuclide. Two complementary functions.
HoliRods™ combines a therapeutic beta-emission pathway and an imaging gamma-emission pathway, enabling treatment, visualisation and quantitative assessment within the same theranostic concept.
Beta emission delivers localised radiation dose to the tumour region.
Gamma emission enables SPECT/CT visualisation and supports quantitative assessment.
More than a formulation — an integrated treatment platform.
The development pathway links non-radioactive manufacture, neutron activation, image-guided delivery, SPECT/CT verification and patient-specific dosimetry.
Manufacture & QC
Biodegradable Ho-165 precursor microspheres or rods are produced and quality controlled before activation.
Neutron activation
Ho-165 is converted to therapeutic Ho-166 using research-reactor neutron activation.
Targeted delivery
Microspheres are delivered intra-arterially or intratumourally; rods are implanted using image guidance.
SPECT/CT verification
The Ho-166 gamma signal supports localisation and quantitative post-delivery imaging.
Personalised dosimetry
Quantitative images are converted into activity and absorbed-dose maps to support treatment assessment.
One platform, two routes of delivery.
The holmium-166 platform is being developed in biodegradable microsphere and solid rod configurations to support different image-guided locoregional approaches.
Holmium-166 Microspheres
Biodegradable holmium-166 microspheres designed for injection-based delivery, including intra-arterial and intratumoural approaches within the development programme.
- Biodegradable polymer carrier
- Therapy + SPECT/CT imaging
- Locoregional delivery concept
HoliRods™
Solid biodegradable rods designed for image-guided implantation into or near tumour targets using a needle-based delivery approach.
- Image-guided implantation
- Highly localised treatment concept
- Theranostic imaging capability
Building a defensible Malaysian theranostic technology base.
A related granted Malaysian patent, MY-210234-A, covers a microsphere platform combining a chemotherapeutic drug with a neutron-activatable radioactive agent. The patent is owned by Taylor’s University and lists Yeong Chai Hong and Wong Yin How as inventors.
One implementation example combines doxorubicin, a Ho-165 precursor and biodegradable PHBV polymer, followed by neutron activation to form Ho-166 chemo-radioactive microspheres. This creates a potential pathway toward local chemotherapy, beta-radiation therapy and gamma-based imaging within a single locoregional platform.
Therasynthesis is developing its broader Ho-166 platform around locally manufacturable products, quantitative imaging, personalised dosimetry and future clinical translation.
From TRL 6 toward clinical and commercial translation.
The programme is currently positioned at Technology Readiness Level 6, with an end-to-end prototype workflow demonstrated in a relevant environment.
The planned roadmap progresses through manufacturing scale-up, preclinical validation, quality systems, regulatory preparation and phased clinical evaluation.
basic research TRL 6
prototype demonstrated TRL 9
market-ready target
Facility & quality setup
Infrastructure, SOPs and quality-by-design systems.
Engineering batches
Process establishment, qualification and reproducible production.
Preclinical proof-of-concept
Optimisation, biocompatibility, sterility and small-animal studies.
GLP & quality systems
Large-animal work, safety package and ISO 13485 implementation.
Early clinical evaluation
Planned safety, feasibility, imaging and dosimetry assessment, subject to approvals.
Clinical & commercial translation
Further clinical evaluation, market validation and scale-up planning, subject to approvals.
A programme built on more than a decade of theranostic research.
The scientific programme underpinning Therasynthesis has received regional and international recognition across nuclear medicine, medical physics and translational innovation.
Multidisciplinary expertise across engineering, medical physics and clinical translation.
Professor Dr Basri Johan Jeet Abdullah
Clinical translation, image-guided procedures and clinical protocol development.
+6016 675 7895bjja2016@gmail.comProfessor Dato’ Ir. Dr. Mohammed Rafiq Bin Dato’ Abdul Kadir
Project governance, milestone delivery, stakeholder engagement and biomedical engineering leadership.
+6013 7585 553rafiqkadir@um.edu.myProfessor Dr. Yeong Chai Hong
Research strategy, formulation, imaging dosimetry and scientific oversight across preclinical and clinical development.
+6016 701 6875yeongchaihong@gmail.comDatuk Dr. Harjit Singh
Clinical indications, patient selection, treatment endpoints and clinical trial co-oversight.
Partner with a Malaysian theranostic innovation company.
We welcome discussions with hospitals, research institutions, nuclear technology partners, manufacturers, investors and strategic collaborators.
Start a conversation
Therasynthesis Sdn Bhd
2147, Sri Senawang Industrial Area
Batu 4 1/2, Jalan Tampin
70450 Senawang
Seremban, Negeri Sembilan
Malaysia
Registration No.
202501004516 (1605929-U)
Development notice: HoliRods™ is an investigational technology platform under development. Website content describes research, development and planned translational activities and should not be interpreted as regulatory approval, clinical availability or established clinical benefit.